CLAIMS

1. Use of an inhibiting agent in the preparation of a pharmaceutical composition for preventing, inhibiting or treating a *P. gingivalis* infection in a subject, wherein the inhibiting agent prevents, inhibits or reduces a *P. gingivalis* biofilm and is an inhibitor of fumarate reductase activity.

2. Use of an inhibiting agent in the preparation of a pharmaceutical composition for preventing, inhibiting or treating periodontal disease in a subject, wherein the inhibiting agent prevents, inhibits or reduces a *P. gingivalis* biofilm and is an inhibitor of fumarate reductase activity.

3. The use of claim 1 or 2, wherein the fumarate reductase activity is a bacterial fumarate reductase activity.

4. The use of claim ~~6~~3, wherein the fumarate reductase corresponds to accession number AAQ66643 or AAQ66642.

5. The use of any one of claims 1 to 4, wherein the inhibiting agent is selected from the group consisting of oxantel, morantel and thiabendazole.

6. The use of claim 5, wherein the inhibiting agent is oxantel.

7. The use of claim 5, wherein the inhibiting agent is morantel.

8. The use of claim 5, wherein the inhibiting agent is thiabendazole.

9. The use of any one of claims 1 to 8, further comprising the use of an antibiotic.